2022
Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone. Hepato Pancreato Biliary 2022, 24: s90-s91. DOI: 10.1016/j.hpb.2022.05.170.Peer-Reviewed Original Research
2020
Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients
Deig C, Trone K, Beneville B, Stratton A, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Attia F, Bassale S, Chen Y, Keith D, Chen E, Lopez C, Gilbert E, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e581-e582. DOI: 10.1016/j.ijrobp.2020.07.1786.Peer-Reviewed Original ResearchHepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program
Walker B, Billingsley K, Sutton T, Zarour L, Kolbeck K, Korngold E, Chen E, Kardosh A, Herzig D, Tsikitis V, Nabavizadeh N, Dewey E, Lopez C, Mayo S. Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program. Hepato Pancreato Biliary 2020, 22: s123-s124. DOI: 10.1016/j.hpb.2020.04.630.Peer-Reviewed Original Research
2016
Aggressive approach to hepatic resection and adjuvant tyrosine kinase inhibitor therapy for metastatic gastrointestinal stroma tumors: Outcomes on survival
Pichardo E, Castillo A, Heinrich M, Billingsley K. Aggressive approach to hepatic resection and adjuvant tyrosine kinase inhibitor therapy for metastatic gastrointestinal stroma tumors: Outcomes on survival. Hepato Pancreato Biliary 2016, 18: e171. DOI: 10.1016/j.hpb.2016.02.408.Peer-Reviewed Original Research
2014
The international normalized ratio overestimates coagulopathy in patients after major hepatectomy
Louis S, Barton J, Riha G, Orloff S, Sheppard B, Pommier R, Underwood S, Differding J, Schreiber M, Billingsley K. The international normalized ratio overestimates coagulopathy in patients after major hepatectomy. The American Journal Of Surgery 2014, 207: 723-727. PMID: 24791634, DOI: 10.1016/j.amjsurg.2013.12.021.Peer-Reviewed Original ResearchConceptsInternational normalized ratioMajor hepatectomyNormalized ratioPatient populationElevated international normalized ratioUse of thrombelastographyPostoperative day 1Postoperative time pointsHypercoagulable statePreoperative valuesDecreased incidenceProcoagulant factorsTEG measurementsCoagulation factorsDay 1ThrombelastographyHepatectomyFactor VIIISubsequent normalizationPatientsTime pointsHypocoagulabilityTherapyProtein C.
2011
Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma (HCC): Rationale and Preliminary Data Supporting Hypothesis-driven Prospective Clinical Trial Development
Fuss M, Schwartz J, Naugler W, Urquhart J, Orloff S, Billingsley K, Vaccaro G, Koslin B, Kolbeck K, Kaufman J. Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma (HCC): Rationale and Preliminary Data Supporting Hypothesis-driven Prospective Clinical Trial Development. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s170. DOI: 10.1016/j.ijrobp.2011.06.1677.Peer-Reviewed Original ResearchA Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma
Bicquart C, Youssef R, Wissel A, Sheppard B, Billingsley K, Thomas C, Wang S. A Nomogram for Predicting the Benefit of Adjuvant Therapy for Resected Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s561. DOI: 10.1016/j.ijrobp.2011.06.887.Peer-Reviewed Original Research
2008
Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
Morris A, Billingsley K, Hayanga A, Matthews B, Baldwin L, Birkmeyer J. Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer. Journal Of The National Cancer Institute 2008, 100: 1740-1740. PMID: 18477800, PMCID: PMC2766763, DOI: 10.1093/jnci/djn396.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantConfidence IntervalsDecision MakingFemaleHealth Services AccessibilityHealthcare DisparitiesHumansLogistic ModelsMaleMedical OncologyMedical Record LinkageMedicareNeoplasm StagingPractice Patterns, Physicians'Radiation OncologyRadiotherapy, AdjuvantRectal NeoplasmsReferral and ConsultationSEER ProgramUnited StatesWhite PeopleConceptsRectal cancerAdjuvant therapyBlack patientsWhite patientsRadiation oncologistsAdjuvant treatmentMedical oncologistsEnd Results-Medicare dataProvider decision makingPatient-provider interactionsFrequency of consultationsLow treatment ratesClinical characteristicsElderly patientsConsultation ratesOncology referralTreatment disparitiesPatient preferencesProvider characteristicsRadiation therapyPatientsOncologistsTherapyStage IITreatment rates
2006
Current Status of Colorectal Cancer Therapy
Strother J, Billingsley K, Hung A, Blanke C. Current Status of Colorectal Cancer Therapy. 2006, 273-285. DOI: 10.1007/978-1-59745-172-7_23.Peer-Reviewed Original Research